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Stargardt disease (STGD) or fundus flavimaculatus is a progressive form of juvenile macular degeneration with considerable clinical and genetic heterogeneity. It may be 
considered a syndromal cone-rod dystrophy due to overlapping 
clinical features such as loss of color vision and photophobia in 
some patients. The most common symptom of STGD is variable, 
often slow loss of central vision in both eyes. Some people also 
develop color blindness later in the disease. The progression of 
symptoms in STGD is different for each person. People with an 
earlier onset of disease tend to have more rapid vision loss. Vision 
loss may decrease slowly at first, and then worsen rapidly until it 
levels off.
Mutations in a gene called ABCA4 are the most common 
cause of STGD [1,2]. This gene makes a protein that normally 
clears away Vitamin A byproducts inside the photoreceptors. 
Cells that lack the ABCA4 protein accumulate clumps of 
lipofuscin, a fatty substance that forms yellowish flecks. As 
the clumps of lipofuscin increase in and around the macula, 
central vision becomes impaired. Eventually, these fatty deposits 
lead to the death of photoreceptors and vision becomes further 
impaired. Mutations in the ABCA4 gene are also associated 
with other retinal dystrophies including cone dystrophy, cone-
rod dystrophy, and retinitis pigmentosa, a severe form of retinal 
degeneration. Furthermore, mutations in at least four genes are 
responsible for similar clinical characteristics. Due to the lack of 
diagnostic distinctions and the wide range of nonspecific clinical 
manifestations, STGD and fundus flavimaculatus are discussed 
here as a single entity. The incidence of this disease is about 1 in 
10,000, and hence, we are reporting a case of this rare disease.
CASE REPORT
A 32-year-old female presented to us with progressive vision 
deterioration since last 18 months to the present status of vision 
being 6/12 (best corrected in both eyes). General physical 
examination and systemic examination was unremarkable. On 
examination, the best-corrected visual acuity was 6/12 in both 
eyes, with normal anterior segment examination. On fundus 
examination, the posterior pole had yellowish pisiform, round, 
and linear sub-retinal lipofuscin deposits which extending to 
equator more in the left than in the right eye. Retinal vessel calibre 
was normal (Figs. 1 and 2).
Fluorescein angiography revealed window in the macula 
where the retinal pigment epithelium (RPE) is atrophied. The 
flecks were hyperfluorescent. Patches of angiographically dark 
choroid in the posterior pole were seen (Figs. 3 and 4). Provisional 
diagnosis of fundus flavimaculatus was made. As no definitive 
treatment is available, the patient was called for regular follow-up 
to cater for low vision aids if required in the future and for earlier 
diagnosis and management of choroidal neovascular membrane 
at the earliest. The best-corrected visual acuity remained constant 
at 6/12 for 1 year with the patient being on 3-month follow-up.
DISCUSSION
STGD or fundus flavimaculatus is a group of fundus dystrophy 
characterized by onset of vision loss late in the first decade 
of life usually with rapid progression in Stargardt and much 
later third decade or so, or even into the fifth decade in fundus 
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flavimaculatus [3]. There is evidence that patients with an early 
onset have a worse prognosis compared to those with a later onset. 
Nevertheless, large series of patients contain at least 23% with 
20/40 or better acuity, about 20% with 20/50–20/100, and 55% 
have 20/200–20/400, and a small number have vision <20/4003.
Some color discrimination is lost and photophobia may be a 
complaint. Dark adaptation is prolonged but night blindness does 
not usually occur and peripheral visual fields are normal. The 
posterior pole characteristically has yellowish pisiform, round, 
and linear sub-retinal lipofuscin deposits which often extend to 
the equator. These may be present before clinical symptoms are 
present. Histopathology reveals accumulations of this material in 
RPE cells. Atrophy of the RPE in the same region is often visible 
as well, but these changes may be subtle initially. Some patients 
have peripheral pigment clumping which may resemble the bone 
spicule configuration seen in retinitis pigmentosa. However, 
retinal vessel caliber is normal in STGD. Extensive macular 
disease can be associated with temporal pallor of the optic nerve. 
The ERG shows reduced photonic responses with normal or near 
normal scotopic tracings. Fluorescein angiography often reveals 
more extensive disease than seen on fundoscopy. Window defects 
are common in the macula where the RPE is atrophied. The 
flecks may be hypofluorescent or hyperfluorescent. Over 50% 
of patients have patches of angiographically dark choroid in the 
posterior pole which is thought to be secondary to transmission 
blockage by lipofuscin accumulations in the RPE.
This group of disorders may be caused by mutations in at least 
four genes. These are STGD1 (248200) caused by mutations in the 
ABCA4 gene located at 1p22.1, or in CNGB3 (262300) (8q21-q22) 
which also is mutant in achromatopsia 3, STGD3 (605512) caused 
by mutations in the ELOVL4 gene at 6q14, and STGD4 (603786) 
caused by a mutation in PROM1 on chromosome 4p. STGD4 and 
STGD3 diseases have been found in pedigrees consistent with 
autosomal dominant inheritance, but STGD1 disease seems to be 
inherited in an autosomal recessive pattern [3].
There is considerable diagnostic confusion regarding the 
clinical phenotypes and the classification of many patients. 
In particular, areolar macular dystrophy, retinitis pigmentosa, 
juvenile macular degeneration, and cone dystrophies have been 
reported in association with several of these mutations and reports 
have also associated STGD with mutations in RDS. Recent 
evidence suggests that gene-retinal phenotype correlations in this 
disorder are especially variable and inconsistent adding to the 
diagnostic confusion [4,5]. Low vision aids are useful for patients 
with advanced disease and patients are advised to avoid sunlight 
to prevent buildup of lipofuscin [4].
Figure 1: Fundus photo of the left eye
Figure 2: Fundus photo of the right eye
Figure 3: Fundus fluorescein angiography of the left eye
Figure 4: Fundus fluorescein angiography of the right eye
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CONCLUSION
Currently, there is no treatment for STGD. Some 
ophthalmologists encourage people with STGD to wear dark 
glasses and hats when out in bright light to reduce the buildup 
of lipofuscin. Cigarette smoking and secondhand smoke should 
be avoided. We just advised a regular follow-up and an yearly 
checkup to the patient.
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